ArticlePloS one2011
Ex vivo expansion of human hematopoietic stem cells by garcinol, a potent inhibitor of histone acetyltransferase.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Natural compounds from traditional Chinese medicine regulating stem cell fate: Identification and therapeutic potential.Chinese herbal medicines · 2025Review
- Ex vivo expansion of human hematopoietic stem cells and clinical applications.Cancer science · 2024Review
- Influential factors for optimizing and strengthening mesenchymal stem cells and hematopoietic stem cells co-culture.Molecular biology reports · 2024Review
- Insights into highly engraftable hematopoietic cells from 27-year cryopreserved umbilical cord blood.Cell reports. Medicine · 2023Article
- Luteotropic and Luteolytic Factors Modulate the Expression of Nuclear Receptor Coregulators in Bovine Luteal Cells Independently of Histone Acetyltransferase and Histone Deacetylase Activities.Animals : an open access journal from MDPI · 2023Article
- Review
- Ex Vivo Expansion and Homing of Human Cord Blood Hematopoietic Stem Cells.Advances in experimental medicine and biology · 2023Article
- Clinical Progress and Preclinical Insights Into Umbilical Cord Blood Transplantation Improvement.Stem cells translational medicine · 2022Review
- Development and clinical advancement of small molecules forActa pharmaceutica Sinica. B · 2022Review
- [Research progress on in vitro expansion and clinical application of hematopoietic stem cell].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Synthesis and Multiplexed Activity Profiling of Synthetic Acylphloroglucinol Scaffolds.Angewandte Chemie (International ed. in English) · 2021Article
- Effect of Small Molecule onFrontiers in cell and developmental biology · 2021Review
- Chromatin-modifying drugs and metabolites in cell fate control.Cell proliferation · 2020Review
- Isoform-specific involvement of Brpf1 in expansion of adult hematopoietic stem and progenitor cells.Journal of molecular cell biology · 2020Article
- Development of Small Molecule MEIS Inhibitors that modulate HSC activity.Scientific reports · 2020Article
- Past, present, and future efforts to enhance the efficacy of cord blood hematopoietic cell transplantation.F1000Research · 2019Review
- Ex Vivo Expansion of CD34Stem cells translational medicine · 2018Article
- Syntheses of (+)-30-epi-, (-)-6-epi-, (±)-6,30-epi-13,14-Didehydroxyisogarcinol and (±)-6,30-epi-Garcimultiflorone A Utilizing Highly Diastereoselective, Lewis Acid-Controlled Cyclizations.Journal of the American Chemical Society · 2016Article
- Novel chemical attempts at ex vivo hematopoietic stem cell expansion.International journal of hematology · 2016Review
- Todralazine protects zebrafish from lethal effects of ionizing radiation: role of hematopoietic cell expansion.Zebrafish · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman cord blood (hCB) is the main source of hematopoietic stem and progenitor cells (HSCs/PCs) for transplantation. Efforts to overcome relative shortages of HSCs/PCs have led to technologies to expand HSCs/PCs ex vivo. However, methods suitable for clinical practice have yet to be fully established. METHODOLOGY/PRINCIPAL
findingsIn this study, we screened biologically active natural products for activity to promote expansion of hCB HSCs/PCs ex vivo, and identified Garcinol, a plant-derived histone acetyltransferase (HAT) inhibitor, as a novel stimulator of hCB HSC/PC expansion. During a 7-day culture of CD34(+)CD38(-) HSCs supplemented with stem cell factor and thrombopoietin, Garcinol increased numbers of CD34(+)CD38(-) HSCs/PCs more than 4.5-fold and Isogarcinol, a derivative of Garcinol, 7.4-fold. Furthermore, during a 7-day culture of CD34(+) HSCs/PCs, Garcinol expanded the number of SCID-repopulating cells (SRCs) 2.5-fold. We also demonstrated that the capacity of Garcinol and its derivatives to expand HSCs/PCs was closely correlated with their inhibitory effect on HAT. The Garcinol derivatives which expanded HSCs/PCs inhibited the HAT activity and acetylation of histones, while inactive derivatives did not. CONCLUSIONS/SIGNIFICANCE: Our findings identify Garcinol as the first natural product acting on HSCs/PCs and suggest the inhibition of HAT to be an alternative approach for manipulating HSCs/PCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.